Chronic blood losse from the hemodialyzer, dialysis technique and phlebotomy complicates the course of maintenance hemodialysis therapy and, consequently, routine oral or parenteral iron supplements are usually prescribed. Until recently, the status of the patients' iron stores could be determined reliably only by serial bone marrow aspiration. The commercial availability of an immunoradiometric assay of serum ferritin (1), a high molecular weight iron storage protein, has made routine screening of dialysis patients possible. Ferritin correlates well with bone marrow iron stores (2, 3) (normal 80-350 ng/ml (2)) and total body iron (1 ng/ml = 8 mg storage iron (4)). A ferritin level of> 350 ng/ml suggests systemic iron overload in the absence of acute of chronic liver disease, infection, malignancy, or hemolysis (5) .
Recently routine ferritin screening in one hemodialysis center has disclosed severe iron overload (ferritin level> 1000 ng/ml) in 54% of patients receiving 2.6 grams of parenteral iron per year (6) . Until recently parenteral iron, given as iron-dextran, was felt to be the ideal form of iron replacement therapy, as it is taken up by the reticuloendothelial system and delivered to the bone marrow for erythropoiesis. This latter step, however, is impaired, in chronic illnesses (7) including uremia, precluding the use of intravenous iron as a physiologic substitute for iron absorbed from the gut.
Oral iron is now believed to be well absorbed in renal failure (6, 8) and its absorption is thought to vary according to the needs of the body (6, 8) . Yet oral iron can also produce iron overload (9) . Why iron overload may develops from oral supplements in unclear, but some patients may have genetic predisposition resembling that of idiopathic hemochromatosis. It now appears that the alleles regulating iron metabolism in idiopathic hemochromatosis may be linked to certain HLA-antigens and their presence in dialysis patients may predispose to iron overload. We have shown recently that patients with the antigens predisposing to idiopathic hemochromatosis (HLA A3, 87, or 814) have a significantly greater incidence of iron over load, as determined by serum ferritin levels greater than 1000 ng/ml (10) .
The manifestations of severe iron overload in dialysis patients were formally considered benign, despite autopsy evidence of extensive iron deposition in the liver, spleen, heart, pancreas, and adrenals (11) . Recent evidence suggesteds that iron overload may cause liver cirrhosis (9) and proximal myopathy (10) and the death of 3 patients with cirrhosis emphasizes the hazards of iron overload. Of perhaps even greater importance is the knowledge that iron may be deposited in the hearts of non-uremic patients with transfusional iron overload and skeletal muscle iron deposition (12) . As supraventricular arrhythmias and congestive heart failure correlate with the extent of myocardial siderosis (12) , one can speculate that severe iron overload could contribute to the high rate of cardiovascular disease in maintenance dialysis patients.
The treatment of iron overload has been disappointing. With desferrioxamine, an iron chelator, given by continuous subcutaneous infusion, the iron is removed mainly through the urine (13) in anephric patients a small amount of the chelate, ferrioxamine, is excreted in bile, but most of it is removed by hemodialysis. Dialysate iron will increase to a maximum of 45 mg per treatment after the infusion of 2 gms of desferrioxamine (14) , mobilizing a maximum of 7 gms of iron per year (assuming 3 hemodialysis treatments per week). Prolonged treatment is necessary because the total body excess iron is greater than 5 gms in an iron overloaded patient.
Ascorbic acid has also been used to increase urinary iron excretion but may do so by releasing reticuloendothelial iron into the circulation, where it can be further deposited into the parenchyma. Cardiac function in eight out of ten patients with thalassemia deteriorated when ascorbic acid was added to desferrioxamine and improved in five of eleven when ascorbate was stopped (15) .
It thus appears that iron overload in dialysis patients is difficult to treat and potentially associated with considerable morbidity. It is best prevented by avoiding parenteral iron or frequent blood transfusion and by monitoring serum ferritin levels periodically. Patients judged to be iron overloaded should not receive oral iron supplements (common in certain multivitamin preparations) and should be treated with desferrioxamine if liver or muscle involvement is demonstrated on biopsy. Tissue typing is recommended at the commencement of dialysis. In patients with HLA-A3, 87, or 814, special care should be taken to avoid iron administration.
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Editorial
The anemia of patients undergoing maintenance hemodialysis is invariably compound by chronic blood loss and iron deficiency. Because dialysis patients often require close laboratory monitoring, the frequent and often extensive blood sampling for diagnostic tests is a major cause of blood loss. Although the amount of blood lost depends largely on the practices of each institution, it is also proportional to the severity of patients' illness. Consequently the sickest and most unstable patients lose the most blood, which they can in afford.
Several investigators have studied this problem of blood loss from laboratory tests (1) (2) (3) (4) (5) (6) . They have generally shown that home-dialysis patients use less blood than in-center patients, whose lossess range from 1130 to 3216 ml per year. This represents a considerable loss for patients already suffering from anemia and its disabling consequences. To minimize this iatrogenic loss we recently introduced a number of simple measures to reduce blood loss from diagnostic tests. Of these the most effective was the adoption of micronanalytic laboratory services, this reduced the average blood loss from 1130 to 122 ml per year, saving of more than 90 per cent (6) .
Microanalytic laboratory methods have been used by pediatric services for many years. Their accuracy is comparable to that of conventional methods since similar procedures and equipments are used. An incorrect notion has existed that microanalytic methods cause certain errors, such as underestimating the hematocrit and platelet count, and overestimating the plasma potassium. These errors, however, result from blood being drawn from the finger or heel, not from the analytic methods, and should not occur when blood is taken from the dialysis lines or by venipuncture. Most laboratories can handle minisampies without having to modifing their equipment. It is stransburged, therefore, that dialysis facilities should adopt microanalytic laboratory services.
In addition to sending blood samples to the laboratory, hematocrits and clotting time determinations are usually carried out in the unit by nurses or technicians. Althoug only two to four drops of blood are required for the microhematocrit method, we noted in our unit that 0.5-1.0 ml of blood was being drawn for this purpose
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